To assess the safety and tolerability of vamikibart, an intravitreal anti–interleukin-6 monoclonal antibody, in patients with noninfectious uveitic macular edema.
Key Findings:
No sustained intraocular pressure elevations or new cataracts were reported with vamikibart.
No drug-related serious adverse events occurred; one patient had worsening uveitis unrelated to the drug.
Mean best-corrected visual acuity improvements were observed, with scores improving by 10.7 and 9.0 in lower dose groups.
Over 80% of participants had complete resolution of intraretinal fluid by week 12.
Interpretation:
Intravitreal interleukin-6 inhibition may positively affect intraocular inflammation and macular edema, but findings are preliminary.
Limitations:
Small sample size and lack of randomization.
Absence of a control group limits distinguishing treatment effects from natural disease progression.
Inclusion of various uveitis subtypes without stratification may confound results.
Conclusion:
While vamikibart shows promise in safety and preliminary efficacy, further evaluation in ongoing phase 3 trials is necessary.
